Liquid purification or separation – Processes – Ion exchange or selective sorption
Reexamination Certificate
2001-09-25
2004-09-14
Cintins, Ivars C. (Department: 1724)
Liquid purification or separation
Processes
Ion exchange or selective sorption
C210S692000
Reexamination Certificate
active
06790365
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to an adsorbent for adsorbing and removing endogenous cannabinoid from body fluid, a process for adsorbing and removing endogenous cannabinoid, and an adsorber for endogenous cannabinoid using the same.
It is known that cannabinoids, the main substance of the physiological action of marijuana (cannabis), brings about mental effects such as hallucination and feeling of euphoria. As cannnabinoid receptors, a receptor (CB1) expressed in central nerves and a receptor (CB2) expressed in peripheral immune cells are known. Endogenous ligands to these cannabinoid receptors, i.e., the ligand generated in living bodies are called endogenous cannabinoid. Known examples of the endogenous cannabinoid are anandamide and 2-arachidonoylglycerol (hereinafter referred to as 2-AG).
The endogenous cannabinoid bears various physiological activities such as (1) drop in blood pressure and bradycardia for cardiovascular system, (2) inhibition of NO generation in macrophages for immune system, (3) defect of memory and inhibition of pain sensation for central nerve system, and (4) induction of endothelial cell apoptosis for coagulation fibrinolysis system.
Recently, it became clear that anandamide is generated in macrophage and 2-AG is generated in blood platelet by means of lipopolysaccharide stimulus (hereinafter referred to as LPS). It is also observed that the generated endogenous cannabinoid causes drop in blood pressure. Furthermore, some raises possibility that the endogenous cannabinoid generated in macrophage or blood platelet is responsible for the blood pressure drop in septic shock. In fact, there is a report that concentrated endogenous cannabinoid was detected in the blood of patients with septic shock.
From these facts, a treatment is expected for the blood pressure drop in septic shock and the like by removing endogenous cannabinoid from body fluid of patients. However, no process for adsorbing and removing endogenous cannabinoid has been available so far. Hence, there has been considerable demand for such process. Yin Wang et al reported that the adsorption of anandamide was possible by means of a substance obtained by fixing an antibiotic, polymyxin B (FEBS Letters, vol. 470, pp151-155, 2000). However, many steps are required in order to prepare such an adsorbent. Besides, the polymyxin B, one of the antibiotics, is very expensive. For these reasons, there is a desire for a process for adsorbing and removing endogenous cannabinoid by using a lower-price substance.
The present invention was carried out in order to solve the above problems. The object of the present invention is to provide an adsorbent which can adsorb and remove endogenous cannabinoid in body fluid efficiently, a process for adsorbing and removing endogenous cannabinoid in body fluid by using the adsorbent, and an adsorber for endogenous cannabinoid.
SUMMARY OF THE INVENTION
Intense studies were conducted as to an adsorbent which can adsorb and remove endogenous cannabinoid in body fluid efficiently. As a result, the present invention has been completed based on the findings that an adsorbent comprising a water-insoluble material containing a substance whose solubility parameter &dgr; is at most 12 ((cal/cm
3
)
1/2
) can adsorb and remove endogenous cannabinoid efficiently.
That is, the present invention relates to an adsorbent for endogenous cannabinoid comprising a water-insoluble material containing a substance whose solubility parameter &dgr; is at most 12 ((cal/ cm
3
)
1/2
).
The water-insoluble material is preferably a styrene-divinyl benzene copolymer.
The endogenous cannabinoid is preferably anandamide.
The endogenous cannabinoid is preferably 2-AG.
The present invention also relates to a process for adsorbing and removing endogenous cannabinoid comprising a step of contacting the adsorbent of endogenous cannabinoid with fluid containing endogenous cannabinoid.
The fluid is body fluid in a preferred embodiment.
The present invention also relates to an adsorber for endogenous cannabinoid comprising a container having a fluid inlet, a fluid outlet and a means for preventing the adsorbent from escaping outside the container, wherein the container is filled with the adsorbent of endogenous cannabinoid.
REFERENCES:
patent: 3625652 (1971-12-01), Fujimoto et al.
patent: 3625830 (1971-12-01), Bergy et al.
patent: 3888250 (1975-06-01), Hill
patent: 4425237 (1984-01-01), Abe et al.
patent: 4640909 (1987-02-01), Ramsden et al.
patent: 4990458 (1991-02-01), Rosenfeld
patent: 5015589 (1991-05-01), Ostrea, Jr.
patent: 5062959 (1991-11-01), Ross et al.
patent: 5137626 (1992-08-01), Parry et al.
patent: 6057161 (2000-05-01), Nau
patent: 6475478 (2002-11-01), Hirai et al.
patent: 249274 (1987-09-01), None
patent: 0796865 (1997-09-01), None
patent: 0834350 (1998-04-01), None
patent: 1110602 (2001-06-01), None
Yin Wang et al, “Polymyxin B binds to anandamide and inhibits its cytotoxic effect”; Fed. European Biochem. Societies;FEBS Lettersvol. 470, pp. 151-155 (2000) (XP-002181222).
European Search Report dated Nov. 19, 2001.
Fujimoto Tamiji
Furuyoshi Shigeo
Hirai Fumiyasu
Sakurai Hiroshi
Cintins Ivars C.
Kaneka Corporation
Westerman Hattori Daniels & Adrian LLP
LandOfFree
Process for adsorbing and removing endogenous cannabinoid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for adsorbing and removing endogenous cannabinoid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for adsorbing and removing endogenous cannabinoid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3269436